Beacon Pharmaceuticals (DHA:BEACONPHAR) Total Liabilities : BDT11,440 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Beacon Pharmaceuticals Total Liabilities?

Beacon Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was BDT11,440 Mil.

Beacon Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2023 (BDT8,700.08 Mil) to Sep. 2023 (BDT8,848.40 Mil) and increased from Sep. 2023 (BDT8,848.40 Mil) to Dec. 2023 (BDT11,440.06 Mil).

Beacon Pharmaceuticals's annual Total Liabilities increased from Jun. 2021 (BDT3,180.41 Mil) to Jun. 2022 (BDT4,872.05 Mil) and increased from Jun. 2022 (BDT4,872.05 Mil) to Jun. 2023 (BDT8,700.08 Mil).

Beacon Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Beacon Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beacon Pharmaceuticals Total Liabilities Chart

Beacon Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

2,017.09

2,546.56

3,180.41

4,872.05

8,700.08

Beacon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															6,056.35	8,185.90	8,700.08	8,848.40	11,440.06

Beacon Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Beacon Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7814.168	+	(772.479	+	113.436
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8,700

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	14642.107	-	5942.024
	=	8,700

Beacon Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9381.142	+	(1960.198	+	98.717000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	11,440

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	17763.953	-	6323.897
	=	11,440

Beacon Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Beacon Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Beacon Pharmaceuticals (DHA:BEACONPHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beacon Pharmaceuticals PLC (DHA:BEACONPHAR) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

9/B/2, Toyenbee Circular Road, Motijheel C/A, Beacon Business Centre, Dhaka, BGD, 1223

Website

https://www.beaconpharma.com.bd

Beacon Pharmaceuticals PLC manufactures and markets pharmaceutical products. Its products are used in various therapeutic areas, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, and muscle relaxants. The company exports its products to Europe, America, Australia, Africa, and Asia. The company's products can be segmented as General, Chronic Care, Oncology, and Biotech products.

Beacon Pharmaceuticals (DHA:BEACONPHAR) Headlines

No Headlines